Compile Data Set for Download or QSAR
Report error Found 284 Enz. Inhib. hit(s) with all data for entry = 9216
TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311854(US10166214, Example 1 | US10675268, Example 1)
Affinity DataEC50:  238nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311864(US10166214, Example 2 | US10675268, Example 2)
Affinity DataEC50:  56.5nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311867(US10166214, Example 3 | US10675268, Example 3)
Affinity DataEC50:  179nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311868(US10166214, Example 4 | US10675268, Example 4)
Affinity DataEC50:  315nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311869(US10166214, Example 5 | US10675268, Example 5)
Affinity DataEC50:  26.6nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311870(US10166214, Example 6 | US10675268, Example 6)
Affinity DataEC50:  59.6nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311871(US10166214, Example 7 | US10675268, Example 7)
Affinity DataEC50:  435nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311872(US10166214, Example 8 | US10675268, Example 8)
Affinity DataEC50:  2.80nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM450244(US10675268, Example 9)
Affinity DataEC50:  536nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311874(US10166214, Example 10 | US10675268, Example 10)
Affinity DataEC50:  10.7nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311875(US10166214, Example 11 | US9789082, Example 11 | U...)
Affinity DataEC50:  8.10nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311876(US10166214, Example 12 | US10675268, Example 12)
Affinity DataEC50:  0.600nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311877(US10166214, Example 13 | US10675268, Example 13)
Affinity DataEC50:  2.40nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311878(US10166214, Example 14 | US10675268, Example 14)
Affinity DataEC50:  7.20nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311879(US10166214, Example 15 | US10675268, Example 15)
Affinity DataEC50:  7.80nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311880(US10166214, Example 16 | US10675268, Example 16)
Affinity DataEC50:  192nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311881(US10166214, Example 17 | US10675268, Example 17)
Affinity DataEC50:  1nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311882(US10166214, Example 18 | US10675268, Example 18)
Affinity DataEC50:  20.4nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311883(US10166214, Example 19 | US10675268, Example 19)
Affinity DataEC50:  141nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311884(US10166214, Example 20 | US10675268, Example 20)
Affinity DataEC50:  8.5nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311885(US10166214, Example 21 | US9789082, Example 21 | U...)
Affinity DataEC50:  0.700nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM50081058(CHEMBL3421842 | US10166214, Example 22 | US9789082...)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311887(US10166214, Example 23 | US10675268, Example 23)
Affinity DataEC50:  17.5nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311888(US10166214, Example 24 | US9789082, Example 24 | U...)
Affinity DataEC50:  0.5nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311889(US10166214, Example 25 | US9789082, Example 25 | U...)
Affinity DataEC50:  14.8nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311890(US10166214, Example 26 | US10675268, Example 26)
Affinity DataEC50:  46.5nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311891(US10166214, Example 27 | US10675268, Example 27)
Affinity DataEC50:  285nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311892(US10166214, Example 28 | US10675268, Example 28)
Affinity DataEC50:  11.3nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311893(US10166214, Example 29 | US10675268, Example 29)
Affinity DataEC50:  60.4nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311894(US10166214, Example 30 | US10675268, Example 30)
Affinity DataEC50:  202nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311895(US10166214, Example 31 | US10675268, Example 31)
Affinity DataEC50:  1.90nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311896(US10166214, Example 32 | US10675268, Example 32)
Affinity DataEC50:  9.90nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311897(US10166214, Example 33 | US10675268, Example 33)
Affinity DataEC50:  4.60nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311898(US10166214, Example 34 | US10675268, Example 34)
Affinity DataEC50:  41.1nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311899(US10166214, Example 35 | US10675268, Example 35)
Affinity DataEC50:  376nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311900(US10166214, Example 36 | US10675268, Example 36)
Affinity DataEC50:  21.8nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311901(US10166214, Example 37 | US10675268, Example 37)
Affinity DataEC50:  162nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311902(US10166214, Example 38 | US10675268, Example 38)
Affinity DataEC50:  27.8nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311903(US10166214, Example 39 | US10675268, Example 39)
Affinity DataEC50:  3nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311904(US10166214, Example 40 | US9789082, Example 40 | U...)
Affinity DataEC50:  5nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311905(US10166214, Example 41 | US10675268, Example 41)
Affinity DataEC50:  194nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311906(US10166214, Example 42 | US10675268, Example 42)
Affinity DataEC50:  14.7nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311907(US10166214, Example 43 | US10675268, Example 43)
Affinity DataEC50:  185nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311908(US10166214, Example 44 | US10675268, Example 44)
Affinity DataEC50:  361nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311909(US10166214, Example 45 | US10675268, Example 45)
Affinity DataEC50:  1.20nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311910(US10166214, Example 46 | US10675268, Example 46)
Affinity DataEC50:  241nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US9789082, Example 47 | U...)
Affinity DataEC50:  3.70nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311912(US10166214, Example 48 | US10675268, Example 48)
Affinity DataEC50:  3.70nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM50081055(CHEMBL3421843 | US10166214, Example 49 | US9789082...)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311914(US10166214, Example 50 | US10675268, Example 50)
Affinity DataEC50:  8.40nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 284 total ) | Next | Last >>
Jump to: